label: IWG-MRT Myelodysplastic Syndrome Minor Hematologic Improvement-Erythroid Response in High Transfusion Burden
label_lc: iwg-mrt myelodysplastic syndrome minor hematologic improvement-erythroid response in high transfusion burden
description: "Minor hematologic improvement-erythroid response in high transfusion burden patients is defined as a reduction by at least 50% of RBCs over a minimum of 8 weeks with the same transfusion policy (defined in \"1.2.4. Transfusion policy\") compared with 16 weeks prior to treatment. Only a response duration of at least 16 weeks, however, is considered clinically meaningful. (Adapted from Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials; Blood 2019 133: 1020-1030)"